Transcenta Holding Limited (HKEX:06628), a China-based clinical stage biopharmaceutical company, announced on Wednesday that it has dosed its first subject in the United States phase one study of TST003 (NCT05731271), its first-in-class, high affinity humanised monoclonal antibody targeting Gremlin1, intended to treat solid tumours.
NCT05731271 is an open-label, dose escalation, FIH study designed to evaluate the safety, tolerability, and pharmacokinetics profile of TST003 as a treatment in patients with solid tumours. The company said that TST003 has demonstrated promising single agent and combination activities in patient-derived xenograft tumour models from the difficult-to-treat solid tumours resistant to checkpoint inhibitors including castration resistant prostate cancer and microsatellite stable colorectal cancer.
Dr Caroline Germa, Transcenta's EVP, Global Medicine Development and CMO, said, 'The enrolment and dosing of the first patient in the US marks a very significant milestone for TST003: our carefully designed Phase 1 will provide the necessary clinical and translational data to achieve the full potential of targeting Gremlin1 as a single agent or in combinations with standard of care, in particular in indications with high unmet need like MSS CRC or CRPC.'
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients